Pseudomonas entering the post-genomic era.

V. de Lorenzo

IF: 5.476

Environmental Microbiology

Abstract:

What problem does this paper attempt to address?

The Effect of Azithromycin in Treating Mycoplasma Pneumonia in Children

Hong Zhou,Hongjuan Xu,Lihong Wang,Shuying Fang,Yehua Zhang

DOI: https://doi.org/10.26689/jcnr.v7i6.5644

2023-11-27

Journal of Clinical and Nursing Research

Abstract:Objective: To discuss and analyze the effect of azithromycin in the treatment of mycoplasma pneumonia in children. Methods: A total of 120 children with mycoplasma pneumonia who were admitted to the Department of Pediatrics of our hospital from January 2022 to December 2022 were selected as the research subjects. They were divided into an azithromycin group and a reference group according to the random number drawing method, with 60 cases in each group. The azithromycin group was treated with azithromycin, and the reference group was treated with conventional treatment. The efficacy of treatment, laboratory indicators, platelet count and D-dimer, and adverse reactions of both groups were compared. Results: The efficacy of the azithromycin group was significantly higher than that of the reference group (P 0.05); after treatment, the laboratory indicators of the azithromycin group were significantly better than those of the reference group (P 0.05); after medication, the platelet count, and D-dimer in the azithromycin group were significantly better than those in the reference group (P < 0.05). The total incidence of adverse reactions in the azithromycin group was significantly lower than that in the reference group (P < 0.05). Conclusion: Azithromycin is more effective in treating mycoplasma pneumonia in children, and has certain clinical value.
Clinical Efficacy of Azithromycin in Treatment of Children’s Mycoplasma Pneumonia

Fan Gui-yin

Abstract:Objective:To observe the effect of azithromycin in treatment of children’s mycoplasma pneumonia clinical curative effect and adverse reaction.Method:Randomized controlled trial,120 patients with children’s mycoplasma pneumonia were divided into azithromycin group(observation group) and erythromycin group(control group),two groups of 60 patients each.The observation group with azithromycin injection,1 times a day;control group using erythromycin injection,2 times a day.Comparison of two clinical efficacy,the time when the symptoms disappear and side effects.Result:Two groups of the total efficiency of the difference was not statistically significant(P0.05),the recovery rate of the differences was statistically significant(P0.05);two groups of the body temperature to restore the normal time,cough disappearance,pulmonary rales disappearance,time of tenth days X-ray absorption cases,hospitalization time difference were statistically significant(P0.05);adverse reaction rate was 16.7% in the observation group,30% in control group,the difference was significant(P0.05).Conclusion:Azithromycin in treatment of mycoplasma pneumonia in children is superior to erythromycin,is relatively shorter course of treatment,clinical symptoms faster,less adverse reactions,drug delivery method is more simple,the compliance of children better advantages.

Medicine
The Timing Of Azithromycin Treatment Is Not Associated With The Clinical Prognosis Of Childhood Mycoplasma Pneumoniae Pneumonia In High Macrolide-Resistant Prevalence Settings

Dehua Yang,Linghong Chen,Zhimin Chen

DOI: https://doi.org/10.1371/journal.pone.0191951

IF: 3.7

2018-01-01

PLoS ONE

Abstract:BackgroundMycoplasma pneumoniae infection is a major cause of community-acquired pneumonia in children. We performed a retrospective study to evaluate the clinical impact of the timing of azithromycin treatment in children with Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.Methods and findingsA total of 623 patients were enrolled in this study and were divided into 2 groups according to the timing of azithromycin therapy. Children who received azithromycin within 3 days (72 hours) after the onset of Mycoplasma pneumoniae pneumonia were classified into the early azithromycin treatment group (n = 174), whereas the late azithromycin treatment group (n = 449) comprised children treated with azithromycin more than 72 hours after symptom onset. We evaluated clinical prognosis according to demographic, clinical and laboratory characteristics. Although the early azithromycin treatment group exhibited a longer fever duration after azithromycin administration (7.17 4.12 versus 4.82 3.99 days, P<0.01), the total fever duration exhibited no significant difference (9.02 4.58 versus 9.57 4.91 days, P = 0.212). After azithromycin therapy, the two groups exhibited no significant differences with respect to improvements in the laboratory and radiological findings (all P>0.05).ConclusionThe timing of azithromycin treatment is not associated with the clinical prognosis of Mycoplasma pneumoniae pneumonia in children in high macrolide-resistant Mycoplasma pneumoniae prevalence settings.
Analysis of the Efficacy of Erythromycin Cyclic 11,12-Carbonate Combined with Azithromycin in the Treatment of Severe Mycoplasma Pneumoniae Pneumonia in Children and its Effect on Cytokines

Dong Ran,Li Jie,Wu Jiannan,Hu Wenjun,Yan Lulu,Le Jing

DOI: https://doi.org/10.17352/aprc.000087

2024-08-27

Archives of Pulmonology and Respiratory Care

Abstract:Introduction: Mycoplasma Pneumoniae Pneumonia (MPP) is an inflammation of the lungs caused by Mycoplasma pneumoniae infection. Macrolide antibiotics are the therapeutic agents of choice for MPP. This study aimed to explore the efficacy of erythromycin cyclic 11,12-carbonate combined with azithromycin in treating children with severe Mycoplasma pneumoniae pneumonia (SMPP). Methods: 84 children with SMPP treated at Hubei Maternal and Child Health Hospital between February 2021 and December 2021 were randomly divided into two groups. The control group was treated with intravenous azithromycin and then changed to oral azithromycin. The experimental group was treated with intravenous azithromycin and then switched to oral erythromycin cyclic 11,12-carbonate. The clinical efficacy, symptom improvement, inflammatory levels, and cytokine levels before and after treatment were compared, and the occurrence of adverse reactions was recorded. Results: The overall effective rate of treatment in the experimental group was significantly higher than that in the control group (P<0.05). The time to the disappearance of clinical symptoms and length of hospitalization of the experimental group was significantly shorter than that of the control group (P<0.05). After treatment, inflammatory levels and cytokine levels of the experimental group were significantly lower than those of the control group (P 0.05). Conclusion: Erythromycin cyclic 11,12-carbonate combined with azithromycin in the treatment of children with SMPP had significant efficacy, superior to azithromycin monotherapy, which could effectively improve immune function and clinical symptoms.
Efficacy of Azithromycin plus Glucocorticoid Adjuvant Therapy on Serum Inflammatory Factor Levels and Incidence of Adverse Reactions in Children with Mycoplasma Pneumonia

Yingdong Cao,Binbin Dong,Xuecheng Wang,Chunrong Wang

DOI: https://doi.org/10.1155/2022/1207512

2022-04-04

Abstract:Objective. This study was designed to explore the efficacy of azithromycin plus glucocorticoid adjuvant therapy on the levels of serum inflammatory factors and the incidence of adverse reactions in children with mycoplasma pneumonia. Method. A total of 90 eligible children with mycoplasma pneumonia in our hospital from January 2019 to January 2020 were recruited. They were assigned to receive either azithromycin (control group) or azithromycin plus glucocorticoid (experimental group) according to the order of admission. Outcome measures included clinical efficacy, serum inflammatory factor indicators, lung function, clinical symptom mitigation, length of hospital stay, immune function, incidence of adverse reactions, and psychological status of the eligible children. Results. Azithromycin plus glucocorticoid was associated with a significantly higher total clinical efficacy compared with azithromycin P < 0.05 . No significant differences were found in the serum inflammatory factor indices between the two groups P > 0.05 . The children given azithromycin plus glucocorticoid showed lower levels of serum inflammatory factors versus those given azithromycin alone P < 0.001 . Azithromycin plus glucocorticoid outperformed the monotherapy of azithromycin in terms of lung function P < 0.001 . Children after azithromycin plus glucocorticoid therapy had a faster clinical symptom disappearance and shorter length of hospital stay compared with after azithromycin alone P < 0.001 . Azithromycin plus glucocorticoid resulted in higher levels of immune function indices compared with azithromycin alone P < 0.001 . Azithromycin plus glucocorticoid was associated with a lower incidence of adverse reactions compared with azithromycin P < 0.05 . Lower Children’s Depression Inventory (CDI) scores were witnessed in children given azithromycin plus glucocorticoid compared with monotherapy of azithromycin P < 0.001 . Conclusion. Azithromycin plus glucocorticoid in children with mycoplasma pneumonia can effectively improve the clinical indicators of the children with promising efficacy and high safety, which is worthy of promotion and application.

integrative & complementary medicine
Effect of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia

Yan Ni,Meixin Fang,Juping Jiang,Qiongqing Lou,Licheng Wu,Zhiyun Liu

2023-01-15

Abstract:Objective: This study was designed to investigate the clinical efficacy of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia (MPP). Methods: The clinical data of 103 children with MPP treated in Fuyang District Hospital of Traditional Chinese Medicine of Hangzhou from December 2020 to August 2021 were selected and retrospectively analyzed, and these children were divided into a control group (n=51, azithromycin treatment) and a study group (n=52, azithromycin plus ambroxol treatment) according to the different treatment methods. The immunoglobulin level, pulmonary function score, treatment efficacy, serum cytokine level, disappearance time of signs and symptoms, and myocardial enzyme indices were observed and compared between the two groups. Univariate and multivariate analyses were conducted to screen the factors affecting the prognosis of MPP patients. Results: After treatment, the study group showed significantly lower levels of immunoglobulin E, immunoglobulin G, immunoglobulin M and immunoglobulin A; higher pulmonary function scores, and lower levels of interleukin-6, human interferon-gamma, and monocyte chemoattractant protein-4 compared with the control group (all P < 0.05). The total incidence of adverse reactions such as nausea, diarrhea, abdominal pain, and vomiting was 15.38% in the study group, which was slightly lower than that in the control group (17.65%), exhibiting no significant difference (P > 0.05). The disappearance time of cough and lung rales, time required to restore to a normal body temperature, and hospital stay in the study group were shorter than those in the control group (P < 0.05). After treatment, aspartate aminotransferase, lactate dehydrogenase, creatine kinase, and creatine kinase isoenzyme in the study group were lower than those in the control group (all P < 0.05). The course of disease before admission, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anemia, albumin < 30 g/L, drug initiation time, pulmonary consolidation, and complications involving multiple systems were the main factors affecting the efficacy of azithromycin combined with ambroxol in the treatment of MPP. Conclusion: Azithromycin combined with ambroxol can effectively improve the immunoglobulin level and lung function, reduce the level of inflammatory factors, improve the therapeutic effect, shorten the recovery process, and reduce the degree of myocardial damage, which is effective in the treatment of MPP and is worth promoting.
Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children

Rui Han,Qianqian Yu,Guohui Zhang,Baoqiang Li,Shuzhen Han,Guiying Li

DOI: https://doi.org/10.12669/pjms.36.2.1441

2019-12-15

Pakistan Journal of Medical Sciences

Abstract:Objective: To study and compare the clinical effects of azithromycin and erythromycin on children with mycoplasma pneumonia. Methods: Total 132 children with mycoplasma pneumonia who were admitted to our hospital between November 2017 and September 2018 were selected as the research subjects. All the children were divided into an observation group and a control group according to random number table, 66 each. The observation group was treated with azithromycin, while the control group was treated with erythromycin. The therapeutic effect, incidence of adverse reactions and disappearance time of clinical symptoms were compared between the two groups. Results: The total efficacy of the observation group was 98.04%, and that of the control group was 74.51%; there was a significant difference (X2=7.184, P=0.007). The incidence of adverse reactions in the observation group was 15.69%, significantly lower than that in the control group (41.18%) (X2=6.376, P=0.002). The disappearance of fever, cough, rale and X ray shadow of the observation group was significantly earlier than that of the control group, and the difference was statistically significant (P<0.05). Conclusion: Compared with erythromycin, azithromycin is more effective in the treatment of mycoplasma pneumonia in children. Azithromycin can further shorten the improvement time of clinical symptoms and signs and has few adverse reactions and high safety. It is worth clinical application. doi: https://doi.org/10.12669/pjms.36.2.1441 How to cite this:Han R, Yu Q, Zhang G, Li B, Han S, Li G. Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children. Pak J Med Sci. 2020;36(2):156-159. doi: https://doi.org/10.12669/pjms.36.2.1441 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

medicine, general & internal
Efficacy and safety of Azithromycin and Erythromycin for respiratory mycoplasma infection in children: a meta-analysis

PANG Jun,JIN Yu,MA Bin,YANG Ke-hu,CHEN Jing

2012-01-01

Abstract:Objective To study the efficacy and safety of Azithromycin and that of Erythromycin for respiratory Mycoplasma infection in children. Methods All RCTs about Azithromycin and Erythromycin for Mycoplasma pneumonia were searched in PubMed,Embase,Cochrane Library, CNKI,VIPH,Wanfang database,etc,until Feb,2012. We included the RCTs that compared Azithromycin with other medicine in the treatment of respiratory Mycoplasma infection in children.The quality evalutions were under the Cochrane Handbook 5.0.2, and the data were combined quantitatively by RevMan 5.0 software. Results There were 4 RCTs concluded. Three researches were to compare "Azithromycin oral VS Erythromycin oral". One research was to compare "Azithromycin oral VS Erythromycin ivgtt". Totally 538 children, Azithromycin oral group 319, control group 219. The Meta-analysis results showed that the clinical response conditions were as follows: the clinical response of "Azithromycin oral group" was better than "Erythromycin oral group" during the period ≤15 days or ≥1 month,there being no statistical difference between "Azithromycin oral group" and "Erythromycin ivgtt group" during the period ≤15 days after the treatment. Adverse effects: compared with "Erythromycin oral"and "Erythromycin ivgtt" group, the children in the "Azithromycin oral"group suffered less diarrhea and/ or vomiting after the treatment(OR = 0.22,95%CI:0.11～0.43;OR = 0.23, 95%CI:0.12～0.42). Conclusion In the treatment of respiratory Mycoplasma infection in children, the clinical effect of oral Azithromycin is better than that of oral Erythromycin during the period ≤15 days or ≥1 month, while the former effect is of no statistical difference from Erythromycin ivgtt. Adverse reactions: compared to erythromycin oral or ivgtt,the patients in Azithromycin oral group tend to have less diarrhoea and/ or vomiting. All in all,Azithromycin is a good choice for the treatment of respiratory Mycoplasma infection in children.
Study on the Therapeutic Effect of Azithromycin Combined with Glucocorticoid on Pulmonary Function and Inflammatory Response in Children with Pneumonia

Qingchun Zhao,Junbo Yang,Yongmei Sheng,Min Zhuang,Min Qi

DOI: https://doi.org/10.1155/2022/5288148

2022-03-27

Journal of Healthcare Engineering

Abstract:Objective. The objective is to explore the efficacy of azithromycin combined with glucocorticoids in the treatment of children with pneumonia and its effect on the inflammatory response. Methods. A total of 86 children with pneumonia were divided into the experimental group (EG) and the control group (CG). Both groups received conventional treatment, the CG was treated with azithromycin and the EG was additionally treated with glucocorticoid methylprednisolone. The therapeutic effect, disappearance time of clinical symptoms, pulmonary function, inflammatory factors, immune function, quality of life, and adverse reactions were measured in the two groups. Results. After treatment, compared with CG, the total effective rate was significantly elevated, the disappearance time of various clinical symptoms was earlier, and various pulmonary function indexes were increased in the EG. The interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C reactive protein (CRP), and CD8+ levels were reduced, and CD3+ and CD4+ levels were increased in the EG. The quality-of-life scores were upregulated in the EG. Moreover, there was no significant difference in the incidence of adverse reactions between the two groups. Conclusion. The combined use of azithromycin and glucocorticoids in the treatment of children with Mycoplasma pneumoniae infection has a good curative effect, can significantly improve lung function, restore pulmonary inflammatory indexes to normal, and enhance patients’ immune function and improve their quality of life, with fewer adverse reactions and safety.

health care sciences & services
Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children

Xiang-Feng Li,Qianye Zhao,Yu-Na Chai,M. Shao,F. Duan,Wen-Sheng Zhai,Jian-Li Qiu,Hui-juan Zhang,Xiao-Xu Sun,Li Huang

DOI: https://doi.org/10.1097/MD.0000000000020121

IF: 1.6

2020-05-29

Medicine

Abstract:Abstract Introduction: The aim of this study was to evaluate the efficacy and safety of azithromycin (AZI) combined with glucocorticoid (GC) in the treatment of children with refractory Mycoplasma pneumoniae. Methods: Computer search for PubMed, EMbase, Cochrane Library, China Biomedical Literature Database (CBMdisc), China Knowledge Network (CNKI), Wanfang, VIP (VIP), and a randomized controlled trial (RCT) of AZI combined with GC in the treatment of children with refractory Mycoplasma pneumoniae pneumonia test (RCT), the search time limit is built until March 20, 2019. Two researchers independently performed literature screening, data extraction, and literature risk bias, and meta-analysis was performed using RevMan 5.3 software. Results: A total of 12 RCTs were included, including 1130 patients. Meta-analysis showed that AZI combined with GC therapy significantly improved the total effective rate of the disease compared with the conventional treatment group (odds ratio [OR] = 6.37; 95% confidence interval [CI] 4.03, 10.07; P < .00001; I2 = 0%), effectively shortened the antipyretic time (SMD = −2.29; 95% CI −2.70, −1.88; P < .0001); promoted lung inflammation absorption (SMD = −1.89; 95% CI −2.38, −1.40; P < .0001), reduced cough time (SMD = −2.39; 95% CI −2.80, −1.99; P < .0001); shortened hospital stay (SMD = −2.19; 95% CI −3.21, −1.17; P < .0001); improved imaging findings (OR = 5.38; 95% CI 1.09, 26.51, P = .04); reduced inflammation index (SMD = −3.15; 95% CI −4.93, −1.36; P = .004); improved immune function (SMD = 1.29; 95% CI −0.02, 2.60; P < .0001); had no significant adverse reactions (OR = 1.18; 95% CI 0.71, 1.98; P = .53). Conclusions: According to the current limited research evidence, the addition of GCs to the conventional treatment of refractory Mycoplasma pneumoniae in children can improve the clinical efficacy to a certain extent, and the safety is better. However, due to the quality and quantity of the included literature, the conclusions of this study need to be confirmed by more high-quality studies.

Medicine
Erythromycin Cydocarbonate improvement of clinical symptoms of mycoplasma pneumonia and analysis of immunoglobulin level changes and mechanism

Yingwei Bi,Hong Wang,Wei Wang,Shaojie Ma

DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2018.17.004

2018-01-01

Abstract:Objective Analysis of erythromycin Cydocarbonate improvement on clinical symptoms of mycoplasma pneumonia,immunoglobulin levels and mechanism.Methods 94 cases of mycoplasma pneumonia were selected from May 2014 to January 2017 in our hospital,according to random number method divided into control group and observation group.The patients in the control group were treatedwith erythromycin,and the patients in the observation group were treated with cyclopyrithromycin.The therapeutic effects of the two groups were analyzed,and the effects on the improvement of symptoms and the changes of immunoglobulin level were analyzed.Results The observation group of children with fever,cough,rales,X-ray improvement time and hospitalization time were shorter than the control group (P ＜ 0.05).After treatment,the levels of hypersensitive C-reactive protein (hs-CRP),interleukin-8 (IL-8),interleukin-10 (IL-10),interferon-γ (IFN-γ),pulmonary surfactant associated protein (SP-A),soluble intercellular adhesion molecule 1 (sICAM-1) were all increased compared with those before treatment.The levels of serum inflammatory factor and serum immunoglobulin SP-A、sICAM-1 in the observation group were lower than those in the control group (P ＜0.05).Conclusions Erythromycin Cydocarbonate treatment of mycoplasma pneumonia can relieve inflammatory response,regulation of children with SP-A,the level of sICAM-1,improve the immune function of children with mycoplasma pneumonia,achieve the treatment purpose.
The efficacy of azithromycin combined with seven types of Chinese medicine injections in the treatment of Mycoplasma pneumoniae pneumonia in children: a systematic review and Bayesian network meta-analysis

Xinggui Huang,Sian Tao,Chenhao Liu,Xiaoluo Sun,Yule Hao,Yuqi Ma,Yi Liu,Jibin Liu

DOI: https://doi.org/10.3389/fphar.2024.1378445

IF: 5.6

2024-09-24

Frontiers in Pharmacology

Abstract:Mycoplasma pneumoniae pneumonia (MPP) is the predominant community-acquired pneumonia (CAP) in children aged 5 years or older. In recent decades, the annual increase in drug resistance rates of macrolide antibiotics, particularly azithromycin (AZ), has led to complex clinical treatment strategies and substantial healthcare costs associated with MPP. Chinese medicine injections (CMIs), recognized as an effective supplementary therapy, are acknowledged by clinicians in China. It is necessary to explore the efficacy of azithromycin in combination with CMIs. Methods Randomized controlled trials (RCTs) evaluating azithromycin in combination with seven types of CMIs for MPP in children were identified based on inclusion criteria and assessed using the revised Cochrane risk of bias tool (RoB 2.0). R 4.3.1 and STATA 15.0 were employed to generate ranking probabilities and perform network meta-analysis. Competing interventions were ranked using the surface under the cumulative ranking (SUCRA) probabilities. Results A comprehensive analysis was performed on 155 RCTs involving 15,014 patients and 8 therapeutic strategies within this Bayesian network meta-analysis (BNMA). The results indicated that AZ combined with seven types of CMIs was more effective than azithromycin alone in overall outcomes. Notably, azithromycin combined with Chuanhuning injection (AZ + CHN) achieved the highest ranking in improving the clinical effectiveness rate (SUCRA, 80.89%); regarding secondary outcome measures, azithromycin combined with Yanhuning injection (AZ + YHN) had the highest probability of improving four different outcomes: disappearance time of cough (SUCRA, 80.01%), disappearance time of pulmonary rale (SUCRA, 87.77%), disappearance time of fever (SUCRA, 95.70%), and disappearance time of pulmonary shadows in X -ray (SUCRA, 97.34%); furthermore, azithromycin combined with Qingkailing injection (AZ + QKL) was more likely to reduce average hospitalization time (SUCRA, 94.60%). Conclusion This study highlights the potential benefits of seven types of Chinese medicine injections as adjunctive therapy for Mycoplasma pneumoniae pneumonia in children. However, further support and validation of these findings are needed through high-quality randomized controlled trials with larger sample sizes and double-blind designs. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/#recordDetails/ .

pharmacology & pharmacy
Comparative conformational analysis of two endothelin-B antagonists

S. Goldstein,M. Neuwels,P. Culot,E. Differding,C. Dogimont,Yvo van Assche,Marie-Hélène Brichard,Drina Jaspers,G. V. Binst,A. Scarso,J. Hénichart

DOI: https://doi.org/10.1007/BF00119140

1995-11-01

Letters in Peptide Science

Abstract:
Shuanghuanglian oral preparations combined with azithromycin for treatment of Mycoplasma pneumoniae pneumonia in Asian children: A systematic review and meta-analysis of randomized controlled trials

Yingying Peng,Zhe Chen,Yanjiao Li,Qiu Lu,Huanmin Li,Yaowei Han,Dan Sun,Xinmin Li

DOI: https://doi.org/10.1371/journal.pone.0254405

IF: 3.7

2021-07-13

PLoS ONE

Abstract:Background Mycoplasma pneumoniae is one of the main causes of community-acquired pneumonia. Due to the imperfect immune system of children, this also causes Mycoplasma pneumoniae pneumonia (MPP) to be more common in children. Globally, the incidence of MPP in children is gradually increasing. This study was the first to systematically review the clinical efficacy and safety of Shuanghuanglian (SHL) oral preparations combined with azithromycin in the treatment of MPP in children. Methods This study fully retrieved 3 Chinese databases and 5 English databases to search the randomized controlled trials (RCTs) of SHL oral preparations combined with azithromycin in the treatment of children with MPP. The search time is from the inception to September 2020. Data extraction and risk bias evaluation were performed independently by two researchers. We conducted a Meta-analysis of all the outcome indicators. Besides, Meta-regression, subgroup analysis, and heterogeneity analysis were used for the primary outcomes to find the possible potential confounding factors. Results Finally, we included 27 RCTs involving 2884 patients. SHL oral preparations combined with azithromycin were better than azithromycin alone in response rate (RR = 1.14, 95% CI[1.11, 1.18]; low certainty evidence), disappearance time of fever(MD = -1.72, 95% CI[-2.47, -0.97]; low certainty evidence), disappearance time of cough (MD = -2.95, 95% CI[-3.55, -2.34]; low certainty evidence), and disappearance time of pulmonary rales (MD = -2.13, 95% CI[-2.88, -1.38]; low certainty evidence). The Meta-regression results showed that the course of disease, age, and method of administration may be the source of heterogeneity. Subgroup analysis and sensitivity analysis have found that the results were stable. For other related clinical symptoms, T lymphocytes, and Serum inflammatory factors, SHL oral preparations combined with azithromycin was better than azithromycin alone, and the difference was statistically significant. For adverse events with low certainty evidence, safety needs further verification. Conclusion Based on the results of meta-analysis with low certainty evidence, we believed that SHL oral preparations combined with azithromycin likely be effectively improved clinical symptoms compared with azithromycin alone. Low certainty evidence showed that SHL may safety with no serious adverse events. Due to these limitations, the safety needs further verification. More high-quality, multicenter, and large-sample RCTs should be tested and verified in the future.

multidisciplinary sciences
Azithromycin Sequential Therapy Combined with Nebulization Inhalation of Budesonide and Combivent in Treating Mycoplasma Pneumonia in 40 Children Cases

Lu Ping,Lan Changzhao,Wang Hong,Bi Yingwei,Wang Wei,Ma Shaojie

DOI: https://doi.org/10.3969/j.issn.1006-4931.2013.17.058

2013-01-01

Abstract:Objective To observe the clinical effect of the azithromycin sequential therapy combined with nebulization inhalation of budesonide and combivent for treating mycoplasma pneumonia in children. Methods Eighty mycoplasma pneumonia patients admitted to our hospital from October 2010 to December 2012 were randomly divided into the azithromycin sequential therapy group( control group,40 cases) and the azithromycin sequential therapy combined with nebulization inhalation of budesonide and combivent group( experimental group,40 cases). The treatment course was 7 days. The clinical curative effects were compared between the two groups. Results The total effective rate was 92. 50% in the control group and 97. 50% in the experimental group,the difference between the two groups had no statistical significance( P > 0. 05),but the disappearance time of cough and pulmonary rales in the experimental group was significantly shortened compared with the control group( P < 0. 05). Conclusion The azithromycin sequential therapy combined with nebulization inhalation of budesonide and combivent has the synergistic effect on treating mycoplasma pneumonia in children,which can obviously improve the clinical symptoms and signs,and shorten the disease process. It is worthy of clinical promotion.
Efficacy of azithromycin combined with intravenous immunoglobulin in the treatment of refractory mycoplasma pneumoniae pneumonia in children: a meta-analysis

Yuan-yuan Shen,Zi-qiang Feng,Zhong-ping Wang,Xue-qin Wang,Cheng Luo and Qing-zhong Liu

DOI: https://doi.org/10.1186/s12887-024-05150-x

2024-10-26

BMC Pediatrics

Abstract:The incidence of refractory Mycoplasma pneumoniae pneumonia (RMPP) in children is increasing, posing a serious threat to life safety. Intravenous immunoglobulin (IVIG) has demonstrated the ability to modulate the immune system and has shown the potential to treat RMPP. This study evaluated the clinical efficacy and safety of azithromycin combined with IVIG in the treatment of RMPP in children through a meta-analysis.

pediatrics
National action plan to reduce smoking during pregnancy: the National Partnership to Help Pregnant Smokers Quit.

T. Orleans,C. Melvin,J. Marx,E. Maibach,Kathryn Kahler Vose

DOI: https://doi.org/10.1080/14622200410001669105

2004-04-01

Nicotine & Tobacco Research

Abstract:Although there has been remarkable progress and momentum toward achieving smoke-free pregnancies in the United States since 1990, concerted action is needed to close the remaining gaps in treatment and prevention so that we can reach the Healthy People 2010 goal for pregnant smokers: a prevalence of 1% or less. This need for action led to the formation of the National Partnership to Help Pregnant Smokers Quit, a collaboration among more than 50 organizations and agencies, public and private, that have joined forces to help pregnant smokers quit by providing proven clinical and community-based interventions to every pregnant smoker. This article summarizes the action plan developed by the partnership, the strategies it outlines, and some of the actions taken by partners over the past year to put the plan into action. Action is planned and progress is being made in five strategic areas: offering help through the health care system; using the media effectively; harnessing community and worksite resources; promoting policies known to increase smoking cessation efforts and successes; and expanding national research, surveillance, and evaluation efforts.
Progress in the Diagnosis and Treatment of Childhood Mycoplasma Pneumoniae Infections

A PUMAROLA,M BELTRAN,E TARDIO,M CRUZ

DOI: https://doi.org/10.3969/j.issn.1000-3606.2008.07.003

2008-01-01

Abstract:Mycoplasma pneumoniae(MP)remains to be an important pathogen of childhood community-acquired pneumonia,and also has close relationship to asthma exacerbation. There is a much higher incidence of MP infection in older children than younger children. The latter,although with a lower infection rate,usually show a more severe clinical picture,and is prone to have tachypnea and retractions. High fever and irritative cough are characteristics of MP infections in older children. Serological method is the standard one for diagnosing MP infection,while PCR is more suitable for early diagnosis of MP infection in younger and immunocompromised patients. Macrolide is still the drug of choice for treatment of childhood MP pneumonia,but how to manage the refractory MP pneumonia has become a big challenge to clinical researchers.
Meta-analysis of combined azithromycin and inhaled budesonide treatment for Chinese pediatric patients with mycoplasma pneumonia

Jing Zhao,Xiaojing Pan,Peng Shao

DOI: https://doi.org/10.1097/md.0000000000038332

IF: 1.6

2024-06-15

Medicine

Abstract:Background: Budesonide, capable of reducing vascular permeability, suppressing mucus secretion, and alleviating edema and spasms, is widely used in China for combined infectious disease treatment. This study assesses budesonide's efficacy and safety as an adjunct to azithromycin in pediatric Mycoplasma pneumonia management in China, aiming to establish a strong theoretical foundation for its clinical application. Methods: We conducted a comprehensive search for qualifying studies across 5 English databases and 4 Chinese databases, covering publications until October 31, 2023. Endpoint analyses were performed using standard software (Stata Corporation, College Station, TX). This study was conducted in compliance with the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Results: A total of 24 randomized controlled trials were involved in the current study, including 2034 patients. Our findings indicate that the combination of budesonide with azithromycin for the treatment of pediatric Mycoplasma pneumonia delivers superior therapeutic efficacy (Intravenous: odds ratio [OR], 0.156, P < .001; Sequential: OR, 0.163, P = .001; Oral: OR, 0.139, P < .001), improved pulmonary function (Forced expiratory volume in 1 second: weighted mean differences [WMD], −0.28, P = .001; Peak expiratory flow: WMD, −0.554, P = .002; Forced vital capacity: WMD, −0.321, P < .001), diminished lung inflammation (IL-6: WMD, 4.760, P = .002; c-reactive protein: WMD, 5.520, P < .001; TNF-α: WMD, 9.124, P < .001), reduced duration of fever, faster resolution of cough and rales, all without increasing the occurrence of adverse events. Conclusion: The combination of budesonide and azithromycin demonstrates enhanced therapeutic effectiveness, promotes improved pulmonary function, shortens the duration of symptoms, and effectively mitigates the overexpression of inflammatory factors like c-reactive protein, TNF-α, and IL-6, all without an associated increase in adverse reactions in pediatric mycoplasma pneumonia.

medicine, general & internal
Clinical Efficacy of Ulinastatin Combined with Azithromycin in the Treatment of Severe Pneumonia in Children and the Effects on Inflammatory Cytokines and Oxidative Stress: A Retrospective Cohort Study

Dongchun Dian,Weilong Zhang,Minjun Lu,Yong Zhong,Yurong Huang,Guiling Chen,Zhangquan Chen,Luxin Yu,Jianbo Sun

DOI: https://doi.org/10.2147/IDR.S428900

2023-11-08

Abstract:Purpose: This retrospective cohort study aimed to evaluate the clinical efficacy of ulinastatin (UTI) and azithromycin (AZM) combination therapy in treating severe pneumonia in children and its impact on inflammatory cytokines and oxidative stress. Patients and methods: This retrospective cohort study was conducted from January 1, 2019, to January 1, 2021, involving pediatric patients diagnosed with severe mycoplasma pneumonia (SMPP). The pediatric patients were divided into two groups: those receiving UTI and AZM combination therapy (treatment group) and those receiving azithromycin alone (control group). We compared the two groups regarding clinical data, disease outcomes, inflammatory cytokines, and oxidative stress levels. Results: Baseline characteristics did not significantly differ between the two groups. UTI, in combination with AZM, significantly improved blood oxygen levels, inflammatory infection markers, and relevant clinical symptoms in patients with SMPP on the 3rd day of treatment. Additionally, it significantly reduced the levels of inflammatory cytokines TNF-a, IL-6, IL-1β, and IL-10, as well as oxidative stress markers GSH and SOD. Conclusion: Combining UTI and AZM can rapidly alleviate clinical symptoms and effectively control the progression of patients with SMPP. Therefore, this treatment approach deserves consideration for clinical promotion and utilization.

Pseudomonas entering the post-genomic era.

The Effect of Azithromycin in Treating Mycoplasma Pneumonia in Children

Clinical Efficacy of Azithromycin in Treatment of Children’s Mycoplasma Pneumonia

The Timing Of Azithromycin Treatment Is Not Associated With The Clinical Prognosis Of Childhood Mycoplasma Pneumoniae Pneumonia In High Macrolide-Resistant Prevalence Settings

Analysis of the Efficacy of Erythromycin Cyclic 11,12-Carbonate Combined with Azithromycin in the Treatment of Severe Mycoplasma Pneumoniae Pneumonia in Children and its Effect on Cytokines

Efficacy of Azithromycin plus Glucocorticoid Adjuvant Therapy on Serum Inflammatory Factor Levels and Incidence of Adverse Reactions in Children with Mycoplasma Pneumonia

Effect of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia

Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children

Efficacy and safety of Azithromycin and Erythromycin for respiratory mycoplasma infection in children: a meta-analysis

Study on the Therapeutic Effect of Azithromycin Combined with Glucocorticoid on Pulmonary Function and Inflammatory Response in Children with Pneumonia

Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children

Erythromycin Cydocarbonate improvement of clinical symptoms of mycoplasma pneumonia and analysis of immunoglobulin level changes and mechanism

The efficacy of azithromycin combined with seven types of Chinese medicine injections in the treatment of Mycoplasma pneumoniae pneumonia in children: a systematic review and Bayesian network meta-analysis

Comparative conformational analysis of two endothelin-B antagonists

Shuanghuanglian oral preparations combined with azithromycin for treatment of Mycoplasma pneumoniae pneumonia in Asian children: A systematic review and meta-analysis of randomized controlled trials

Azithromycin Sequential Therapy Combined with Nebulization Inhalation of Budesonide and Combivent in Treating Mycoplasma Pneumonia in 40 Children Cases

Efficacy of azithromycin combined with intravenous immunoglobulin in the treatment of refractory mycoplasma pneumoniae pneumonia in children: a meta-analysis

National action plan to reduce smoking during pregnancy: the National Partnership to Help Pregnant Smokers Quit.

Progress in the Diagnosis and Treatment of Childhood Mycoplasma Pneumoniae Infections

Meta-analysis of combined azithromycin and inhaled budesonide treatment for Chinese pediatric patients with mycoplasma pneumonia

Clinical Efficacy of Ulinastatin Combined with Azithromycin in the Treatment of Severe Pneumonia in Children and the Effects on Inflammatory Cytokines and Oxidative Stress: A Retrospective Cohort Study